P3354
Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung CancerDurvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLCDurvalumab(MEDI4736)/Tremelimumab in Combination With Gemcitabine/Cisplatin in Chemotherapy-naïve Biliary Tract CancerDurvalumab Plus Tremelimumab With Concurrent Radiotherapy for Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation ApproachDurvalumab Plus "Booster" RT for Metastatic Adenocarcinoma Pancreas Cancer Post Chemotherapy (GCC 1598)Durvalumab and Tremelimumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHNAnti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC)Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching BiomarkersStereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell CanerMEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung CancerDo Changes in ctDNA Predict Response for Patients With Oesophageal Cancer Receiving DurvalumabIMFINZI Specific-Clinical Experience Investigation in Patients With NSCLC After Definitive Chemoradiation TherapyDurvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract CancerCabozantinib in Combination With Durvalumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies (CAMILLA)Durvalumab Plus Olaparib Administered Prior to Surgery of Resectable Urothelial Bladder Cancer (NEODURVARIB)A Phase 1 Study to Investigate SNDX-6352 Alone or in Combination With Durvalumab in Patients With Solid TumorsNeoadjuvant Immunoradiation for Resectable Non-Small Cell Lung CancerRadiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell LymphomaA Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural MesotheliomaIPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors1st Line Durvalumab in PS 2 NSCLC PatientsRadiotherapy With Durvalumab Prior to Surgical Resection for HPV Negative Squamous Cell CarcinomaWindow of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast CancerDurvalumab, Tremelimumab and Stereotactic Body Radiation Therapy in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaNeoadjuvant CCRT With Gemcitabine/Durvalumab (MEDI4736) Followed by Adjuvant Gemcitabine/Durvalumab(MEDI4736) in Resectable or Borderline Resectable Pancreatic CancerAssessing the Combination of Durvalumab (MEDI4736) and Trabectedin in Solid TumorsStereotactic Ablative Radiotherapy (SABR) in Combination With Durvalumab and Tremelimumab in Patients With Cervical, Vaginal, or Vulvar CancerStudy of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon CancerDNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Participants With Recurrent or Metastatic Human Papillomavirus Associated CancersAblative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736)Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung CancerNeoadjuvant and Adjuvant Durvalumab in Combination With Neoadjuvant Chemotherapy in Patients With Operable Urothelial Cancer.Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary TractAnti PD-L1 Antibody + Anti CTLA-4 Antibody in Combination With Hormone Therapy in Patients With Hormone Receptor Positive HER2-negative Recurrent or Metastatic Breast CancerStudy of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid MalignanciesA Multicentre Phase II Trial of Durvalumab Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell AdenocarcinomasDurvalumab and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue SarcomaStudy of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer
P4844
191TiP: MYSTIC: a global, phase 3 study of durvalumab (MEDI4736) plus tremelimumab combination therapy or durvalumab monotherapy versus platinum-based chemotherapy (CT) in the first-line treatment of patients (pts) with advanced stage IV NSCLC.Durvalumab for the management of urothelial carcinoma: a short review on the emerging data and therapeutic potentialManagement of Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitor Therapy: a Minireview of Current Clinical GuidelinesImmune checkpoint inhibitors in malignancyTolerability and efficacy of durvalumab in Japanese patients with advanced solid tumorsUnusual radiologic manifestation of pseudoprogression in pulmonary metastases after durvalumab treatment in metastatic bladder urothelial cancerPhase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)
P921
Q58407578-26141f49-4331-ded3-83f4-3c9977e049caQ58407593-2663ea12-408e-f784-59f1-2062917089a3Q58407756-b75ee99b-4a77-c67e-10a9-0ebfbbe53817Q58407789-097c9f49-494e-295f-c586-f73055c5f736Q58407803-391b0f1d-43c9-aca7-e3cb-6fd2531a3938Q58407815-5b94743b-4d1c-b4fe-1528-ec1211db5becQ58407826-da744488-4b48-742f-27ce-394f5b9f84c8Q58407862-c8cd2951-4245-f856-c0ff-886065cf44b4Q58407878-3c2ac6ff-495e-0f76-9779-9b6e1fc56cd3Q58407886-98d733ca-4e20-6dcb-7915-a4c4ae38d454Q58849937-d60674ef-4ca7-d25b-4348-82f9a181b97eQ58850257-1eefd48b-4d20-6912-cb6d-07cfdc3a200eQ62025193-6243130D-65DA-4975-87F9-D8A94AB563EAQ62025986-29CAD43D-A445-44B6-B8C7-DA97CA944CB9Q62810917-5D673E92-14B2-4C31-B7F7-5C235CFD69A2Q62812462-9C2BEE75-6EC8-4334-9E5A-87A637C7A563Q62814902-F6692789-9EF8-488C-A91F-FD1E830ED2E8Q63010840-5D30D05B-7833-4F46-91A2-B63F1839EC8BQ63010999-F8C68E26-786C-4602-BC8F-727D5C8506F9Q63011368-284A71DF-C0C8-41C7-B4EB-00C2BA6B02E2Q63228707-34D1A3C0-0602-47AB-9C4C-F51D4E902BECQ63393632-3954D344-3858-4113-BAE2-3670D5DE3733Q63393902-0B695251-DBCB-4ADF-9759-95AA2B4CC8BDQ63394277-F8D02E4B-9C4D-456B-B977-AFE0B595A326Q63394857-BF674421-040D-486B-8615-5482AFE8DDA9Q63397178-87F16A05-7AC2-4898-9B34-E4DA0C22D613Q63397200-C0D55028-A7DA-444E-8B27-B8CB75D1F5A2Q63400027-143510B8-5A75-41D0-8382-D07FEAEEA441Q63400711-188BEE0E-EAB3-4413-B59F-C175026C2E55Q63401098-F052CF1A-F71D-4281-B711-61D0686538C5Q63401356-065A755D-69B9-4992-AC1B-6D9A653EA3ADQ63401777-92117923-C532-4219-AB4F-4636AC223390Q63403872-3BB755F8-2D72-4AFE-80FE-D20C8E85B2B7Q63404140-92503E56-5631-426A-A602-ED0A1A52AE61Q63404150-E175C69B-6AFD-4447-A2C0-0320A3D6C89EQ63404265-2DE22273-54EA-4E9B-9BFC-486038262266Q63404276-5E6D64E1-95A0-4126-933A-9CCC81A2F035Q63404718-590FA829-2B98-49F9-B251-4866C13A67DCQ63535200-9728806C-915A-4CF4-B5CE-DCED096919EEQ63571880-6EDF6385-A36C-4EC0-B8F5-53F3EEB7EFB7
P4844
Q53157925-3da5b4a4-4a0d-0221-13aa-f18a0bbe8dddQ64081777-E1C66F73-AAF2-4901-AA60-6B74E00FC1B3Q64088643-5E6D7DDA-F54A-400B-BFD3-6B0F07A7EDA7Q64088731-A9DCEF61-714B-4E05-B347-8F9155447DFDQ64117090-9729086A-36B0-4F00-AC6C-EEB765858BDEQ64297952-8D45F6E0-E290-43E5-96D4-E09C02EC7681Q94234587-68CEBCB4-2D40-4A40-8455-55CCB246F859
P921
description
chemesch Verbindung
@lb
chemical compound
@en
chemical compound
@en-ca
chemical compound
@en-gb
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische verbinding
@nl
name
Durvalumab
@de
Durvalumab
@en
Durvalumab
@es
Durvalumab
@fr
Durvalumab
@pt
دوروالومب
@fa
度伐魯單抗
@zh
type
label
Durvalumab
@de
Durvalumab
@en
Durvalumab
@es
Durvalumab
@fr
Durvalumab
@pt
دوروالومب
@fa
度伐魯單抗
@zh
altLabel
MEDI-4736
@en
MEDI4736
@en
prefLabel
Durvalumab
@de
Durvalumab
@en
Durvalumab
@es
Durvalumab
@fr
Durvalumab
@pt
دوروالومب
@fa
度伐魯單抗
@zh
P31
P592
P6366
P2275
durvalumab
@en
P231
1428935-60-7
P267
P592
CHEMBL3301587
P6366
2777742743
P652
28X28X9OKV
P7830
Durvalumab